BACKGROUND AND PURPOSE: Fewer women than men tend to be enrolled in clinical trials of intracerebral hemorrhage. It is unclear whether this reflects lower prevalence of intracerebral hemorrhage in women, selection bias, or poor recruitment efforts. We undertook this study to examine differences between men and women in the reasons for exclusion from the iDEF trial (Intracerebral Hemorrhage Deferoxamine). METHODS: The screen failure log included 29 different reasons for exclusion. Chi-square statistics were used to evaluate the differences in reasons for exclusion between men and women. RESULTS: A total of 38.2% of participants in iDEF were women. Three thousand nine hundred eighty-two women (45.7%) and 4736 men (54.3%) were screen failures (P<0.0001). Similar proportions of women (1.28%) and men (1.73%) were excluded due to inability to obtain consent (P=0.1). Patients or families declined participation in 1.26% of women versus 1.31% of men (P=0.9). More women than men failed screening because of age>80 (22.40% versus 12.61%; adjusted P=0.0007) and preexisting do-not-resuscitate/do-not-intubate (3.69% versus 2.83%; adjusted P=0.067). CONCLUSIONS: Lower rates of women enrollment in the iDEF trial may be attributed to older age. Inability to obtain consent or declining participation was similar between women and men, arguing against selection bias. Our findings should be confirmed in other intracerebral hemorrhage trials to determine best strategies to improve women's representation in future trials.
BACKGROUND AND PURPOSE: Fewer women than men tend to be enrolled in clinical trials of intracerebral hemorrhage. It is unclear whether this reflects lower prevalence of intracerebral hemorrhage in women, selection bias, or poor recruitment efforts. We undertook this study to examine differences between men and women in the reasons for exclusion from the iDEF trial (Intracerebral Hemorrhage Deferoxamine). METHODS: The screen failure log included 29 different reasons for exclusion. Chi-square statistics were used to evaluate the differences in reasons for exclusion between men and women. RESULTS: A total of 38.2% of participants in iDEF were women. Three thousand nine hundred eighty-two women (45.7%) and 4736 men (54.3%) were screen failures (P<0.0001). Similar proportions of women (1.28%) and men (1.73%) were excluded due to inability to obtain consent (P=0.1). Patients or families declined participation in 1.26% of women versus 1.31% of men (P=0.9). More women than men failed screening because of age>80 (22.40% versus 12.61%; adjusted P=0.0007) and preexisting do-not-resuscitate/do-not-intubate (3.69% versus 2.83%; adjusted P=0.067). CONCLUSIONS: Lower rates of women enrollment in the iDEF trial may be attributed to older age. Inability to obtain consent or declining participation was similar between women and men, arguing against selection bias. Our findings should be confirmed in other intracerebral hemorrhage trials to determine best strategies to improve women's representation in future trials.
Entities:
Keywords:
consent; deferoxamine; prevalence; selection bias; sex
Authors: Magdy Selim; Lydia D Foster; Claudia S Moy; Guohua Xi; Michael D Hill; Lewis B Morgenstern; Steven M Greenberg; Michael L James; Vineeta Singh; Wayne M Clark; Casey Norton; Yuko Y Palesch; Sharon D Yeatts Journal: Lancet Neurol Date: 2019-03-18 Impact factor: 44.182
Authors: S L Gall; G Donnan; H M Dewey; R Macdonell; J Sturm; A Gilligan; V Srikanth; A G Thrift Journal: Neurology Date: 2010-02-24 Impact factor: 9.910
Authors: Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn Journal: Lancet Neurol Date: 2010-01-05 Impact factor: 44.182
Authors: Odera Umeano; Barbara Phillips-Bute; Claire E Hailey; Wei Sun; Marisa C Gray; Briana Roulhac-Wilson; David L McDonagh; Peter G Kranz; Daniel T Laskowitz; Michael L James Journal: PLoS One Date: 2013-11-27 Impact factor: 3.240
Authors: Michael L James; Carl D Langefeld; Padmini Sekar; Charles J Moomaw; Mitchell S V Elkind; Bradford B Worrall; Kevin N Sheth; Sharyl R Martini; Jennifer Osborne; Daniel Woo Journal: Neurology Date: 2017-07-14 Impact factor: 9.910